title: [Medical treatment of macular edema].
abstract: Macular edema was first described more than a century ago, and its medical treatment has made great progress thanks to recent pharmacological advances. Administration is topical, local (peri- or intraocular), or systemic. Nonsteroidal anti-inflammatory agents and corticosteroids are the mainstay therapy when inflammation is involved, as well as acetazolamide in many cases. More recently, molecules such as protein kinase-C- beta inhibitors and anti-VEGF agents are already or will soon be available, to add to our therapeutic armamentarium. Perhaps combination therapy will become popular, as is the case with age-related macular degeneration.
authors: Service d'Ophtalmologie, Hôpital de la Timone, Marseille, France. John.Conrath@ap-hm.fr
authors: J
authors: J
authors: Conrath
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D006931:Hyperbaric Oxygenation; D008269:Macular Edema / Q000628:therapy*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D042442:Vascular Endothelial Growth Factors / Q000037:antagonists & inhibitors
chemical_list: D000305:Adrenal Cortex Hormones; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004232:Diuretics; D004791:Enzyme Inhibitors; D042442:Vascular Endothelial Growth Factors; D011493:Protein Kinase C